FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis

Key Points: 1. First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data showed significant reduction in exacerbations in a trial of over 1,700 participants. On August 12, 2025, the U.S. Food and Drug Administration approved Insmed’s Brinsupri (brensocatib) as the first medicine for non-cystic fibrosis bronchiectasis, a […]